base-metals-investing Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
base-metals-investing Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
base-metals-investing Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
base-metals-investing Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
base-metals-investing Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
base-metals-investing Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
base-metals-investing Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
base-metals-investing Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
